In this online CME self-learning program:
Melanoma is a tumor of the melanocytes whose tissue of origin is primarily the skin, although it may also develop occasionally in the: gastrointestinal, genitourinary, or respiratory tracts; ocular or mucosal tissue; or meninges. It is subcategorized into superficial spreading melanoma (70% of cases), nodular melanoma (15-30%), lentigo maligna melanoma (10%-20%), and acral lentiginous melanoma (5%). Risk factors include a positive personal or family history of melanoma, genetic predisposition, and exposure to ultraviolet light. Diagnosis is made by excisional, incisional, or punch skin biopsy while imaging or indirect ophthalmoscopy may be employed to diagnose uveal or choroidal melanoma.
Treatment options for metastatic melanoma have expanded in recent years with the approval of novel therapies, including a BRAF inhibitor and a cytotoxic T-lymphocyte-associated antigen-4 inhibitor, for the treatment of malignant melanoma, providing more targeted therapeutic modalities than previous forms of immunotherapy and conventional, cytotoxic chemotherapy. Other emerging, molecularly targeted forms of therapy are active areas of research.
Agenda:
Introduction, Disclosures |
Updates in the epidemiology, diagnosis, and prevention of malignant melanoma
|
Review of loco-regional disease and treatment modalities Treatment of malignant melanoma Updates in goals of therapy
|
Barriers to optimal care in patients with malignant melanoma [Learning Objective #4]
|
Summary, conclusions, and best practice recap |
Healthcare professionals specializing in: oncology, dermatology, family medicine, internal medicine, or those who otherwise commonly care for patients with malignant melanoma.
Commercial Support Disclosure: This program is supported by educational grants from Genentech and Amgen.
Release Date: February 21, 2014 -- Expiration Date: June 21, 2016
Faculty: Sanjiv Agarwala, MD
By the end of the session the participant will be able to:
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosure: Sanjiv Agarwala, MD has no relevent financial discloses..
Disclosures of Educational Planners: Charles Turck, PharmD is an officer and part owner of ScientiaCME, LLC.
Commercial Support Disclosure: This program is supported by educational grants from Genentech and Amgen.
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.